Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06686420 · ClinicalTrials.gov registry record · NA
Investigation of the Effects of a Bifidobacterial Strain on Bowel Movement in Healthy Adults
A NA study of Infrequent Bowel Movements, sponsored by Morinaga Milk Industry Co..
- Active
- Registry status
- NA
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT06686420: Active NA study of Infrequent Bowel Movements, sponsored by Morinaga Milk Industry Co..
NCT06686420 is a NA study of Infrequent Bowel Movements that is active but no longer recruiting, run by Morinaga Milk Industry Co.. The registered enrollment target is 80 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06686420, a NA study of Infrequent Bowel Movements, is active but no longer recruiting, sponsored by Morinaga Milk Industry Co..
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to investigate whether a supplement containing the B. longum strain works to alleviate constipation in adults. The main questions it aims to answer are: Does a supplement containing the B. longum strain increase the number of spontaneous bowel movements per week, improve stool consistency, and enhance the quality of life? Participants will: Take a supplement containing the B. longum strain or a placebo every day for 8 weeks. Maintain an e-diary as per the instructions. Visit the clinic for screening assessments, baseline, and end of the intervention for stool sample submission.
Primary Outcome
Change in mean weekly frequency of SBM, as measured by the daily bowel diary from baseline to the end of intervention. Frequency will be defined as the mean weekly number of SBM during the 2-week run-in period prior to Visit 2, for baseline, and during the final 2-week period of the intervention prior to Visit 3, for end of intervention.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT B. longum
Study Locations (1)
Illinois
- Atlantia Clinical Trials - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2024-05-01 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
What the registry record for NCT06686420 still lists
NCT06686420 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Infrequent Bowel Movements appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06686420 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT06686420 about?
NCT06686420 is a clinical study titled "Investigation of the Effects of a Bifidobacterial Strain on Bowel Movement in Healthy Adults". The goal of this clinical trial is to investigate whether a supplement containing the B. longum strain works to alleviate constipation in adults. The main questions it aims to answer are: Does a supplement containing the B. longum strain increase the number of spontaneous bowel movements per week,...
What is the current status of trial NCT06686420?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2024-05-01. Estimated completion is 2026-12-31.
What conditions does trial NCT06686420 study?
This clinical trial studies the following conditions: Infrequent Bowel Movements.
What interventions are being tested in trial NCT06686420?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), B. longum (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06686420?
This trial is sponsored by Morinaga Milk Industry Co., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06686420 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06686420's enrollment target sits among peer trials
80 994th of 2000 higher than 941 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI